Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|AEWS1031||COG||A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma: A Groupwide Phase III Study||Pediatric CIRB||Available to Open|
|S1406||SWOG||Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|9892||ETCTN||Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|ACCL1033||COG||A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL: A Group-wide Non-Therapeutic Study||Pediatric CIRB||Available to Open|
|S1706||SWOG||A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-1016||RTOG||Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E2112||ECOG||A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1612||SWOG||A Randomized Phase II/III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older||Adult CIRB - Late Phase Emphasis||Available to Open|
|NRG-GY008||NRG||A Phase II Evaluation of Copanlisib (BAY 80-6946); (IND #130822); A Selective Inhibitor of PI3KCA; in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations||Adult CIRB - Late Phase Emphasis||Available to Open|
|APEC14B1||COG||The Project: Everychild Protocol: A Registry; Eligibility Screening; Biology and Outcome Study||Pediatric CIRB||Available to Open|